Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28065526 | 1.00 | KCNN4 (0.46) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL5085651 | 1.00 | KCNN4 (0.46) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL28061497 | 0.98 | KCNN4 (0.44) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL8370180 | 0.84 | KCNN4 (0.44) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL326016 | 0.82 | SMN1; SMN2 (0.46) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL28049734 | 0.79 | ESR1 (0.58) | CYP2C19CYP1A2CYP2C9CYP2D6ALDH1A1 | |
| SCHEMBL18106924 | 0.79 | MAPT (0.46) | CYP1A2ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL2790358 | 0.78 | TAAR1 (0.50) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL28018766 | 0.78 | CYP2C19 (0.43) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL25366361 | 0.77 | TAAR1 (0.45) | KCNN4TAAR1CYP2C19CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066420-A | Optically resolved Trolox intermediates and process for producing the same | 住友制药株式会社 | 2022-09-16 | — | — | CN | claimed |
| CN-110556578-A | Electrolyte additive, electrolyte containing electrolyte additive and application of electrolyte in lithium ion battery | FUJIAN INST RES STR MATTER CAS | 2019-12-10 | — | — | CN | claimed |
| CN-110297043-A | A kind of analysis method of 2- methylamino -1- phenyl-1-propanol | 上海医药工业研究院 | 2019-10-01 | — | — | CN | claimed |
| CN-107630049-B | The biological preparation method of ephedrine | 武汉茵茂特生物技术有限公司 | 2018-09-21 | — | — | CN | claimed |
| CN-107630050-A | The biological preparation method of pseudoephedrine | 武汉茵茂特生物技术有限公司 | 2018-01-26 | — | — | CN | claimed |
| CN-103717604-B | Replace aminooimidazole and pyridazine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-01 | — | — | CN | claimed |
| CN-103717604-A | Substituted aminoimidazopyridazines | BAYER IP GMBH | 2014-04-09 | — | — | CN | claimed |
| EP-2019679-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | Theracos, Inc. (US) | 2009-02-04 | — | — | EP | claimed |
| WO-2007140191-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| US-4416828-A | Process for the resolution of the racemate S-(carboxymethyl)-(RS)-cysteine (A) | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1983-11-22 | — | — | US | claimed |
| US-4045450-A | Optical resolution of DL-pantolactone | ALPS PHARMACEUTICAL IND. CO., LTD. (JA) | 1977-08-30 | — | — | US | claimed |
| JP-62070346-A | — | — | None | — | — | JP | disclosed |
| CN-115066420-B | Optically resolved Trolox intermediates and methods of making the same | PTC医疗公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-111295373-B | Compositions and methods for treating brain injury | 阿泽凡药物公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-4045450-A | Optical resolution of DL-pantolactone | ALPS PHARMACEUTICAL IND. CO., LTD. (JA) | 1977-08-30 | — | — | US | disclosed |
| US-4045450-A | Optical resolution of DL-pantolactone | ALPS PHARMACEUTICAL IND. CO., LTD. (JA) | 1977-08-30 | — | — | US | disclosed |
| US-3959302-A | Process for the splitting of the racemate of d-1-phenylpropanolamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-05-25 | — | — | US | disclosed |
| US-3959302-A | Process for the splitting of the racemate of d-1-phenylpropanolamine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-05-25 | — | — | US | disclosed |
| US-3947464-A | Salts of phenylpropanolamine with thiazolidine carboxylic acids | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | KCNN4 3169/4885TAAR1 3840/4885CYP2C19 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.